Celgene Announces EC Approval for ABRAXANE Plus Gemcitabine for Treatment of Metastatic Pancreatic Cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation

, today announced that the European Commission (EC) has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer.1